Literature DB >> 25347741

ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway.

G Rajapaksa1, F Nikolos1, I Bado1, R Clarke2, J-Å Gustafsson1, C Thomas1.   

Abstract

Unfolded protein response (UPR) is an adaptive reaction that allows cancer cells to survive endoplasmic reticulum (EnR) stress that is often induced in the tumor microenvironment because of inadequate vascularization. Previous studies report an association between activation of the UPR and reduced sensitivity to antiestrogens and chemotherapeutics in estrogen receptor α (ERα)-positive and triple-negative breast cancers, respectively. ERα has been shown to regulate the expression of a key mediator of the EnR stress response, the X-box-binding protein-1 (XBP-1). Although network prediction models have associated ERβ with the EnR stress response, its role as regulator of the UPR has not been experimentally tested. Here, upregulation of wild-type ERβ (ERβ1) or treatment with ERβ agonists enhanced apoptosis in breast cancer cells in the presence of pharmacological inducers of EnR stress. Targeting the BCL-2 to the EnR of the ERβ1-expressing cells prevented the apoptosis induced by EnR stress but not by non-EnR stress apoptotic stimuli indicating that ERβ1 promotes EnR stress-regulated apoptosis. Downregulation of inositol-requiring kinase 1α (IRE1α) and decreased splicing of XBP-1 were associated with the decreased survival of the EnR-stressed ERβ1-expressing cells. ERβ1 was found to repress the IRE1 pathway of the UPR by inducing degradation of IRE1α. These results suggest that the ability of ERβ1 to target the UPR may offer alternative treatment strategies for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25347741     DOI: 10.1038/onc.2014.343

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

Review 1.  Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate.

Authors:  Robert Clarke; Katherine L Cook; Rong Hu; Caroline O B Facey; Iman Tavassoly; Jessica L Schwartz; William T Baumann; John J Tyson; Jianhua Xuan; Yue Wang; Anni Wärri; Ayesha N Shajahan
Journal:  Cancer Res       Date:  2012-03-15       Impact factor: 12.701

2.  Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

Authors:  C H Yang; A M Gonzalez-Angulo; J M Reuben; D J Booser; L Pusztai; S Krishnamurthy; D Esseltine; J Stec; K R Broglio; R Islam; G N Hortobagyi; M Cristofanilli
Journal:  Ann Oncol       Date:  2006-01-10       Impact factor: 32.976

3.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.

Authors:  Naoko Honma; Rie Horii; Takuji Iwase; Shigehira Saji; Mamoun Younes; Kaiyo Takubo; Masaaki Matsuura; Yoshinori Ito; Futoshi Akiyama; Goi Sakamoto
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

4.  XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response.

Authors:  Ann-Hwee Lee; Neal N Iwakoshi; Laurie H Glimcher
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

5.  Heat shock protein 90 modulates the unfolded protein response by stabilizing IRE1alpha.

Authors:  Monica G Marcu; Melissa Doyle; Anne Bertolotti; David Ron; Linda Hendershot; Len Neckers
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

6.  Synoviolin promotes IRE1 ubiquitination and degradation in synovial fibroblasts from mice with collagen-induced arthritis.

Authors:  Beixue Gao; Sang-Myeong Lee; An Chen; Jinping Zhang; Donna D Zhang; Krishnaswamy Kannan; Robert A Ortmann; Deyu Fang
Journal:  EMBO Rep       Date:  2008-03-28       Impact factor: 8.807

7.  Comparative effects of estradiol, methyl-piperidino-pyrazole, raloxifene, and ICI 182 780 on gene expression in the murine uterus.

Authors:  Angela M Davis; Jiude Mao; Bushra Naz; Jessica A Kohl; Cheryl S Rosenfeld
Journal:  J Mol Endocrinol       Date:  2008-07-16       Impact factor: 5.098

8.  Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer.

Authors:  Robert Clarke; Ayesha N Shajahan; Yue Wang; John J Tyson; Rebecca B Riggins; Louis M Weiner; William T Bauman; Jianhua Xuan; Bai Zhang; Caroline Facey; Harini Aiyer; Katherine Cook; F Edward Hickman; Iman Tavassoly; Anael Verdugo; Chun Chen; Alan Zwart; Anni Wärri; Leena A Hilakivi-Clarke
Journal:  Horm Mol Biol Clin Investig       Date:  2011-03

9.  Ligand-independent activation of estrogen receptor alpha by XBP-1.

Authors:  Lihua Ding; Jinghua Yan; Jianhua Zhu; Hongjun Zhong; Qiujun Lu; Zonghua Wang; Cuifen Huang; Qinong Ye
Journal:  Nucleic Acids Res       Date:  2003-09-15       Impact factor: 16.971

10.  Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients.

Authors:  Abeer M Shaaban; Andrew R Green; Suchita Karthik; Yalda Alizadeh; Thomas A Hughes; Lynn Harkins; Ian O Ellis; John F Robertson; Emma C Paish; Philippa T K Saunders; Nigel P Groome; Valerie Speirs
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

View more
  20 in total

1.  HBV suppresses thapsigargin-induced apoptosis via inhibiting CHOP expression in hepatocellular carcinoma cells.

Authors:  Danqi Zhao; Yan Liu; Xing Liu; Tao Li; Zhenhui Xin; Xilin Zhu; Xiaopan Wu; Ying Liu
Journal:  Oncol Lett       Date:  2017-07-25       Impact factor: 2.967

Review 2.  Estrogen Signaling as a Therapeutic Target in Neurodevelopmental Disorders.

Authors:  Amanda Crider; Anilkumar Pillai
Journal:  J Pharmacol Exp Ther       Date:  2016-10-27       Impact factor: 4.030

3.  The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells.

Authors:  Igor L Bado; Weijie Zhang; Jingyuan Hu; Zhan Xu; Hai Wang; Poonam Sarkar; Lucian Li; Ying-Wooi Wan; Jun Liu; William Wu; Hin Ching Lo; Ik Sun Kim; Swarnima Singh; Mahnaz Janghorban; Aaron M Muscarella; Amit Goldstein; Purba Singh; Hyun-Hwan Jeong; Chaozhong Liu; Rachel Schiff; Shixia Huang; Matthew J Ellis; M Waleed Gaber; Zbigniew Gugala; Zhandong Liu; Xiang H-F Zhang
Journal:  Dev Cell       Date:  2021-04-19       Impact factor: 12.270

Review 4.  Breast cancer in low-middle income countries: abnormality in splicing and lack of targeted treatment options.

Authors:  Flavia Zita Francies; Rodney Hull; Richard Khanyile; Zodwa Dlamini
Journal:  Am J Cancer Res       Date:  2020-05-01       Impact factor: 5.942

Review 5.  Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers.

Authors:  Robert Clarke; Katherine L Cook
Journal:  Front Oncol       Date:  2015-06-22       Impact factor: 6.244

6.  ERβ decreases the invasiveness of triple-negative breast cancer cells by regulating mutant p53 oncogenic function.

Authors:  Igor Bado; Fotis Nikolos; Gayani Rajapaksa; Jan-Åke Gustafsson; Christoforos Thomas
Journal:  Oncotarget       Date:  2016-03-22

7.  Insufficient antibody validation challenges oestrogen receptor beta research.

Authors:  Sandra Andersson; Mårten Sundberg; Nusa Pristovsek; Ahmed Ibrahim; Philip Jonsson; Borbala Katona; Carl-Magnus Clausson; Agata Zieba; Margareta Ramström; Ola Söderberg; Cecilia Williams; Anna Asplund
Journal:  Nat Commun       Date:  2017-06-15       Impact factor: 14.919

8.  The regulation of miR-320a/XBP1 axis through LINC00963 for endoplasmic reticulum stress and autophagy in diffuse large B-cell lymphoma.

Authors:  Yuying Cui; Hui Xu; Yu Yang; Dongmei Zhao; Yu Wen; Chao Lv; Hongbin Qiu; Chennan Wang
Journal:  Cancer Cell Int       Date:  2021-06-10       Impact factor: 5.722

Review 9.  A summary of relationships between alternative splicing and breast cancer.

Authors:  Zhang Xiping; Wei Qingshan; Zhao Shuai; Yang Hongjian; Ding Xiaowen
Journal:  Oncotarget       Date:  2017-05-09

10.  Somatic loss of estrogen receptor beta and p53 synergize to induce breast tumorigenesis.

Authors:  Igor Bado; Fotis Nikolos; Gayani Rajapaksa; Wanfu Wu; Jessica Castaneda; Savitri Krishnamurthy; Paul Webb; Jan-Åke Gustafsson; Christoforos Thomas
Journal:  Breast Cancer Res       Date:  2017-07-03       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.